Carvedilol
- Generic Name
- Carvedilol
- Brand Names
- Coreg
- Drug Type
- Small Molecule
- Chemical Formula
- C24H26N2O4
- CAS Number
- 72956-09-3
- Unique Ingredient Identifier
- 0K47UL67F2
- Background
Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunction, and hypertension. The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs ...
- Indication
Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.
- Associated Conditions
- Atrial Fibrillation, Chronic Stable Angina Pectoris, Hypertension, LVEF ≤40% Left ventricular dysfunction, NYHA Class I or II heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV)
- Associated Therapies
- -
Carvedilol Vascular Efficacy Trial
- First Posted Date
- 2011-12-02
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Elpen Pharmaceutical Co. Inc.
- Target Recruit Count
- 415
- Registration Number
- NCT01484327
- Locations
- 🇬🇷
Cardiology University Clinic, Alexandroupolis, Greece
Ischemia In Hemodialysed Patients: Ivabradine Versus Carvedilol
- Conditions
- Interventions
- First Posted Date
- 2011-08-29
- Last Posted Date
- 2012-06-28
- Lead Sponsor
- University of Campania "Luigi Vanvitelli"
- Target Recruit Count
- 220
- Registration Number
- NCT01425164
- Locations
- 🇮🇹
Chair of Cardiology Second University of Naples, Naples, Italy
Banding Ligation With Carvedilol Versus Carvedilol for the Prevention of First Bleeding
- Conditions
- Interventions
- First Posted Date
- 2011-06-28
- Last Posted Date
- 2020-11-20
- Lead Sponsor
- E-DA Hospital
- Target Recruit Count
- 65
- Registration Number
- NCT01383044
- Locations
- 🇨🇳
E-DA hospital, Kaogsiung, Taiwan
Trial of Carvedilol in Alzheimer's Disease
- First Posted Date
- 2011-05-16
- Last Posted Date
- 2018-02-06
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 29
- Registration Number
- NCT01354444
- Locations
- 🇺🇸
Johns Hopkins School of Medicine Bayview Campus, Baltimore, Maryland, United States
Pharmacological Interaction Between Carvedilol and Methylenedioxymethamphetamine (MDMA)
- Conditions
- Interventions
- First Posted Date
- 2011-01-05
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 16
- Registration Number
- NCT01270672
- Locations
- 🇨🇭
Clinical Pharmacology & Toxicology, University Hospital Basel, Basel, Switzerland
Mechanisms of Improvement With Beta-Blocker Treatment in Heart Failure
- Conditions
- First Posted Date
- 2010-12-16
- Last Posted Date
- 2010-12-16
- Lead Sponsor
- Michael E. DeBakey VA Medical Center
- Target Recruit Count
- 55
- Registration Number
- NCT01261065
- Locations
- 🇺🇸
Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, United States
Comparison of Effect of cARvedilol Compared To bISoprolol on cenTral Pulse Pressure in Hypertension (ARTIST) Study
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- Yoshio Matsui
- Target Recruit Count
- 200
- Registration Number
- NCT01243827
- Locations
- 🇯🇵
Iwakuni City Medical Center, Yamaguchi, Japan
Carvedilol Versus Placebo for Treatment in Post Traumatic Stress Disorder (PTSD)
- First Posted Date
- 2010-10-15
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Columbia Northwest Pharmaceuticals
- Target Recruit Count
- 80
- Registration Number
- NCT01221792
- Locations
- 🇺🇸
Lake Charles Clinical Trials, Lake Charles, Louisiana, United States
🇺🇸Artemis Institute for Clinical Research, San Diego, California, United States
🇺🇸Northwest Clinical Research Center, Bellevue, Washington, United States
Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis
- First Posted Date
- 2010-09-30
- Last Posted Date
- 2019-11-05
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Target Recruit Count
- 132
- Registration Number
- NCT01212250
- Locations
- 🇮🇳
Institute of Liver & Biliary Sciences (ILBS), New Delhi, Delhi, India
Early Primary Prophylaxis of Esophageal Varices
- First Posted Date
- 2010-09-08
- Last Posted Date
- 2016-06-15
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Target Recruit Count
- 140
- Registration Number
- NCT01196507
- Locations
- 🇮🇳
Institute of Liver & Biliary Sciences (ILBS), New Delhi, Delhi, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.